Cramer's Lightning Round: TG Therapeutics is a buy

Written by Emily J. Thompson, Senior Investment Analyst

TGTX-1.36%

RIO+3.59%

Source: CNBC

Updated: Jun 30 2025

0mins

Source: CNBC

Investment Recommendations: Jim Cramer endorses buying stocks in Rio Tinto and TG Therapeutics, expressing confidence in their potential for growth.
Resources for Investors: A guide to investing is available for free, along with an invitation to join the CNBC Investing Club for real-time market insights.

TGTX

$31.2+Infinity%1D

Analyst Views on TGTX

Wall Street analysts forecast TGTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TGTX is 43.50 USD with a low forecast of 15.00 USD and a high forecast of 60.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

4 Analyst Rating

3 Buy

0 Hold

1 Sell

Moderate Buy

Current: 31.630

Low

15.00

Averages

43.50

High

60.00

Current: 31.630

Low

15.00

Averages

43.50

High

60.00

BofA

Alec Stranahan

Underperform

maintain

$13 -> $15

2026-01-06

Reason

BofA

Alec Stranahan

Price Target

$13 -> $15

AI Analysis

2026-01-06

maintain

Underperform

Reason

BofA analyst Alec Stranahan raised the firm's price target on TG Therapeutics to $15 from $13 and keeps an Underperform rating on the shares. The firm is updating its price targets for U.S Biopharmaceuticals under its coverage, the analyst tells investors. Over the past few months, several key items "have fallen into place," including positive data catalysts being rewarded; large-cap biopharma spending cash on M&A and in-licensing; growing backlog of companies on the private side; improving access to capital; and limited impact from drug price regulation, BofA says. The firm believes biotech is back, but the biggest concern is whether this will last.

JPMorgan

Eric Joseph

Overweight

maintain

$46 -> $49

2025-11-03

Reason

JPMorgan

Eric Joseph

Price Target

$46 -> $49

2025-11-03

maintain

Overweight

Reason

JPMorgan analyst Eric Joseph raised the firm's price target on TG Therapeutics to $49 from $46 and keeps an Overweight rating on the shares. The firm updated the company's model post earnings.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for TGTX

Unlock Now

B. Riley

maintain

$53 -> $55

2025-09-17

Reason

B. Riley

Price Target

$53 -> $55

2025-09-17

maintain

Reason

B. Riley raised the firm's price target on TG Therapeutics to $55 from $53 and keeps a Buy rating on the shares. The firm believes the company is positioned for multi-year Briumvi U.S. sales growth. It sees the drug being on track to exceed $1B in the next few years. Riley recommends using the post-earnings selloff in shares of TG as a buying opportunity.

Goldman Sachs

Corinne Johnson

Neutral

initiated

$37

2025-07-10

Reason

Goldman Sachs

Corinne Johnson

Price Target

$37

2025-07-10

initiated

Neutral

Reason

Goldman Sachs analyst Corinne Johnson initiated coverage of TG Therapeutics with a Neutral rating and $37 price target. The firm believes Briuvmi revenue growth will continue to be the key driver of the shares.

About TGTX

TG Therapeutics, Inc. is a fully integrated, commercial stage, biopharmaceutical company. The Company is focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. Its clinical drug candidates are Ublituximab IV (anti-CD20 mAb), Ublituximab Subcutaneous (anti-CD20 mAb), Azer-cel, TG-1701 (BTK inhibitor), and TG-1801 (anti-CD47/CD19 bispecific mAb). BRIUMVI is an anti-CD20 monoclonal antibody for the treatment of RMS, which includes clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. TG-1701 is a novel, orally available and covalently bound Bruton’s tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening. TG-1801 is a bispecific CD47 and CD19 antibody. It also evaluates complementary products, technologies and companies for in-licensing, partnership, acquisition, and/or investment opportunities.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.